Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Riboflavin-Enhanced Hyaluronic Acid Eye Drops in Treating Dry Eye Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria for patient selection included a dry eye history of at least three months, OSDI score ≥ 23, and positivity in at least one eye for one or more of the following diagnostic criteria:~* Tear Break-Up Time (TBUT) \< 7 seconds~* Schirmer test I at 5 minutes \< 10 mm~* Corneal and/or conjunctival fluorescein staining~* Tear osmolarity \> 308 mOsm/L or a difference of at least 8 mOsm/L between both eyes.~Exclusion Criteria:~* Age below 18 years~* Severe ocular surface affections~* Unilateral dry eye syndrome~* Refractive surgery performed within the last six months~* Eye surgery performed within the last three months~* Previous herpetic keratitis~* Signs of active corneal infection~* Systemic or topical steroid therapy within the last 30 days~* Topical therapy within the last 14 days~* Inability to understand the informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group X: Ribohyal Group (Type: None): Composed of 16 eyes (right or left) assigned for the use of modified hyaluronic acid, HAr® 0.1%, covalently linked to Riboflavin
- Group Y: (Control Group) (Type: None): Composed of 16 eyes (right or left) assigned for the use of HA 0.1% alone

Based on this trial design, predict the completion outcome and termination type (if applicable).